Inhibikase Therapeutics, Inc. · NASDAQ:IKT
Inhibikase Therapeutics, Inc. shareholders
As of Jun 30, 2026, 103 institutions reported holding Inhibikase Therapeutics, Inc., 89.1% of its shares. Largest: Sands Capital Alternatives, LLC, Soleus Capital Management, L.P. and Trails Edge Capital Partners, LP. New holders, exits, insiders and big stakes, each with its filing.
| Holder | Shares | % of Inhibikase Therapeutics, Inc. | Change | Filed |
|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 13M | 9.3% | no change | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 10.9M | 7.8% | no change | Aug 11, 2026 |
| Trails Edge Capital Partners, LP | 9.05M | 6.5% | +994K | Aug 14, 2026 |
| Fairmount Funds Management LLC | 8.63M | 6.2% | no change | Aug 14, 2026 |
| BlackRock | 7.77M | 5.6% | +1.46M | Aug 7, 2026 |
| Kalehua Capital Management LLC | 7.64M | 5.5% | +1.15M | Aug 19, 2026 |
| ADAR1 Capital Management, LLC | 7.39M | 5.3% | +781K | Aug 14, 2026 |
| Vanguard | 6.39M | 4.6% | +717K | Aug 13, 2026 |
| Blackstone Inc. | 5.94M | 4.3% | no change | Aug 14, 2026 |
| Siren, L.L.C. | 5.85M | 4.2% | no change | Aug 13, 2026 |